Dr. Michael Chen

Biotech Science Reporter

Molecular biologist turned biotech journalist with PhD in Genetics and 9 years of experience covering drug discovery, clinical trials, and regulatory approvals. Former research scientist who transitioned to journalism to explain breakthrough therapies and biotechnology innovations. Specializes in gene therapy, immunotherapy, rare disease treatments, and the science behind novel drug mechanisms.

AI Author, more information here

Hengrui Secures Next‑Phase Approval for New Drug, Boosting Pipeline Momentum

Jiangsu Hengrui’s June 2026 clearance marks a key clinical‑trial milestone for its next‑gen drug, signaling regulatory progress and potential investor upside while keeping the specifics under wraps.

Dr. Michael Chen

17/06/2026, 12:04

4 minutes to read

Vertex Files Rule 144: Insider Shares Sold, No Impact on CF Pipeline

Vertex Pharmaceuticals’ recent Rule 144 filing shows a routine insider sale of 4,062 shares—no impact on its CF drug pipeline or market position.

Dr. Michael Chen

16/06/2026, 21:38

3 minutes to read

Danaher’s 3‑Year Share Decline: 16% Drop & 127‑Billion‑Dollar Market Cap

Danaher’s modest 16% share decline is driven by market volatility, not science—yet its life‑science pipeline, from liquid biopsies to gene therapy, remains strong and may offer future upside for investors.

Dr. Michael Chen

16/06/2026, 08:32

4 minutes to read

AbbVie’s 45‑70% Rally: Immunology Strengths, Oncology Gains, and Equity Risks

AbbVie’s 45‑53% 2024‑26 rally is driven by strong immunology sales, but a negative equity balance raises risk; new oncology (Epcotinly) and neuromodulation (TrenibotulinumtoxinE) trials signal promising growth, while investors must watch regulatory …

Dr. Michael Chen

12/06/2026, 15:58

5 minutes to read

Danaher Acquires Masimo: Strengthening Precision Diagnostics & Patient Monitoring

Danaher’s acquisition of Masimo boosts precision diagnostics—combining advanced pulse oximetry with molecular tools to improve patient monitoring, speed trials, and enhance outcomes.

Dr. Michael Chen

12/06/2026, 10:30

5 minutes to read

Novo Nordisk Shares Surge as Wegovy Tablet Gains Ground in European Market

Share price rally for Novo Nordisk as Wegovy’s tablet gains market traction, backed by strong clinical data and growing investor confidence in obesity treatment.

Dr. Michael Chen

11/06/2026, 20:25

5 minutes to read

Zoetis Faces Lawsuit Over Alleged Overstatement of Veterinary Product Prospects

Zoetis faces securities‑fraud lawsuits alleging overstatement of veterinary product prospects, raising investor concerns and potential impacts on its pipeline and funding.

Dr. Michael Chen

11/06/2026, 12:40

3 minutes to read

Amgen’s VESALIUS‑CV Trial: Repatha Cuts Cardiovascular Events by 34% in High‑Risk Diabetes

Amgen’s VESALIUS‑CV trial shows Evolocumab cuts major heart events by 34% in high‑risk diabetics, while real‑world GLP‑1 data reveal adherence gaps that need new strategies.

Dr. Michael Chen

10/06/2026, 01:00

4 minutes to read

Roche Holding AG Shares Dip 1.5% as Market Shifts, But Pipeline Momentum Remains Strong

Roche Holding AG shares dip 1.5% amid market wobble, but the firm’s robust pipeline—targeted oncology, gene‑therapy for rare diseases, and antiviral breakthroughs—keeps investors hopeful for strong future growth.

Dr. Michael Chen

09/06/2026, 20:43

5 minutes to read

Novo Nordisk B Unveils 760k‑Ton Inferred Gold Resource at Victoria’s Belltopper Project

New inferred gold resource at Novo Nordisk B’s Belltopper project shows ~87,000 oz at 3.6 g/t—awaiting 2026 drilling to upgrade status and validate economic prospects.

Dr. Michael Chen

09/06/2026, 12:07

3 minutes to read

Newer articles